Hormone-refractory prostate cancer and the skeleton
Soerdjbalie-Maikoe, V.
Citation
Soerdjbalie-Maikoe, V. (2006, February 15). Hormone-refractory prostate cancer and the
skeleton. Retrieved from https://hdl.handle.net/1887/4297
Version:
Corrected Publisher’s Version
License:
Licence agreement concerning inclusion of doctoral thesis in the
Institutional Repository of the University of Leiden
Downloaded from:
https://hdl.handle.net/1887/4297
Chapter 6
Bone scintigraphy predicts the risk of spinal cord
compression in hormone-refractory prostate cancer.
V. Soerdjbalie-Maikoe1, R.C.M. Pelger1, A.A.B. Lycklama a Nijeholt1, J.W. Arndt2, A.H. Zwinderman3, H. Bril5, S.E. Papapoulos4, N.A.T. Hamdy4.
From the Departments of Urology1, Nuclear Medicine2, Medical Statistics3 & Endocrinology and Metabolic Diseases4, Leiden University Medical Center, The
Netherlands and Department of Pathology5, Reinier de Graaf Gasthuis, The Netherlands.
Abstract
Background: In prostate cancer, confirmation of metastatic involvement of the
skeleton has traditionally been achieved by bone scintigraphy, although the widespread availability of prostate-specific antigen (PSA) measurements has tended to eliminate the need for this investigation. The potential of bone scintigraphy to predict skeletal-related events, particularly spinal cord compression, after the onset of hormone refractoriness has never been investigated. The aim of this study was to establish whether a new method of evaluating bone scintigraphy would offer a better predictive value for this complication of the metastatic process than is achieved with currently available grading methods.
Patients and methods: We studied 84 patients with hormone-refractory prostate
cancer who had undergone bone scintigraphy at the time of hormone escape. Tumour grading and parameters of tumour load (PSA and alkaline phosphatase activity) were available in all patients. The incidence of spinal cord compression was documented and all patients were followed up until death. Bone scintigraphy was evaluated by the conventional Soloway grading and by an additional analysis determining total or partial involvement of individual vertebrae.
Results: In contrast to the Soloway method, the new method was able to predict
spinal cord compression at various spinal levels.
Conclusions: Our data suggest that there is still a place for bone scintigraphy in the
Introduction
Prostate cancer is the second leading cause of cancer-related deaths in men over the age of 401. In this malignancy, metastatic spread to the skeleton is the most frequent cause of morbidity and up to 50% of patients may demonstrate skeletal involvement at presentation2. Although most patients respond favourably to androgen deprivation by near-complete regression of osseous metastases, the majority will develop hormone refractoriness, universally associated with the re-appearance of skeletal metastases. Conventional X-rays are on the whole
inadequate for the diagnosis of these metastases so that confirmation of metastatic involvement of the skeleton has traditionally been achieved by bone scintigraphy, which is also used to assess response of the tumour to therapy. In prostate cancer, metastases to the vertebral column predominantly involve the lumbar spine3, but those involving the thoracic spine are associated with the highest morbidity because of their significantly increased risk for spinal cord compression4-7. The question of whether bone scintigraphy could be of value in predicting spinal cord compression after the advent of hormone refractoriness has never been addressed. The aim of this study was to establish whether, compared with the original tumour staging and the prevailing serum prostate-specific antigen (PSA) concentrations, bone scintigraphy performed at the time of hormone refractoriness is of any additional prognostic value regarding survival and skeletal event-free survival (particularly survival without spinal cord compression).
Materials and methods
We studied 84 patients with histologically documented prostate cancer. All patients had been androgen deprived by orchidectomy (n=42), the use of the LH-RH agonist goserelin (n=33) or the use of anti-androgens (n=9). Nineteen patients were also treated with estramustine phosphate. The diagnosis of hormone
scintigraphy. Because of side-effects, hormonal treatment was discontinued in 23 patients and estramustine phosphate in eight. The majority of patients received palliative treatment in the form of radiotherapy (n=4), the radionuclide 89Sr (n=33) or the nitrogen-containing bisphosphonate olpadronate administered intravenously as a single dose of 20 mg (n=41). Six patients responded to conventional analgesia and required no further palliative treatment. Survival was documented in all patients.
Evaluation of tumour load Serum PSA was measured using an MEIA (IMX)
assay. The upper limit of the normal laboratory reference range is 4 µg/l. Serum alkaline phosphatase activity was measured using routine multi-channel analysis. The normal laboratory reference range is 40–120 U/l.
Tumour grading Transrectal needle biopsy of the prostate was available in all
patients. Histological sections were re-examined and tumour restaged by two independent observers (V. S-M. and H.B.) using the Gleason grading system, which is based on the degree of architectural glandular differentiation8-10.
Spinal cord compression The diagnosis of spinal cord compression was
established clinically on the basis of progressive impairment of motor and sensory function and the finding of a segmental level of neurological impairment. The diagnosis was confirmed radiologically by MRI or CT scan of the spine and the level of the lesion was carefully recorded. Spinal cord compression is the most frequently encountered skeletal-related event and the one associated with the highest morbidity. In our study, we defined skeletal event-free survival as survival without spinal cord compression.
Bone scintigraphy All patients underwent bone scintigraphy at the time of
diagnosis of hormone refractoriness using 99mTc-labelled methylene
skeletal involvement with metastases, as follows: grade 0, no metastases; grade 1, less than 6 metastases; grade 2, 6–20 metastases; grade 3, more than 20
metastases; grade 4, superscan (diffuse increased uptake in the axial skeleton without a focal lesion, or more than 75% of the skeleton affected by the metastatic process)11. In addition, we analysed bone scintigrams by evaluating areas of metastatic involvement for extent of involvement of individual vertebrae—total (Fig. 1) or partial (Fig. 2)—and related our findings to subsequent development of spinal cord compression. Bone scintigrams were independently assessed by two of the authors (V.S-M. and J.A.), one of whom is a physician specialising in nuclear medicine (J.A.).
Statistics PSA and alkaline phosphatase activity were not normally distributed and values were log-transformed before statistical analysis. Survival and spinal cord compression-free survival were calculated from date of onset of hormone refractoriness (at which time bone scintigraphy was also performed) until date of death (survival) or date of spinal cord compression (spinal cord compression-free survival). Kaplan-Meier curves were used to express survival, and patient groups were compared using the log-rank test. The prognostic value of scintigraphic parameters for survival and spinal cord compression-free survival was evaluated using the Cox proportional-hazards regression model and the value was quantified using the relative risk and associated 95% confidence interval (CI). The Cox model was also used to test whether scintigraphic parameters contained additional prognostic information over and above that offered by established risk factors such as age, serum PSA concentration and serum alkaline phosphatase activity. A P- value of 0.05 or less was considered statistically significant. Results are expressed as mean±SD values unless otherwise stated.
Results
Survival and spinal cord compression-free survival
evidence of total vertebral involvement went on to develop spinal cord compression respectively 2 days to 8 months and 9 days to 18 weeks after administration of the therapy in question. The remaining eight patients had not received any form of palliative therapy by the time they developed spinal cord compression. Only four patients who demonstrated total involvement of a vertebra did not go on to develop spinal cord compression; all of these patients had
received palliative therapy in the form of olpadronate (n=1), 89Sr (n=1) or local radiotherapy (n=2). All patients with a diagnosis of spinal cord compression were treated with local radiation therapy, which was successful in reversing
neurological abnormalities in all patients except for two who required additional surgical decompression by means of a laminectomy.
Predictive values of markers of tumour load
Serum PSA was elevated in all patients, with a mean value of 511±1,035 µg/l. Serum alkaline phosphatase activity was also elevated in all patients, with a mean value of 402±503 U/l. Whereas log-transformed PSA concentrations were
significantly predictive for survival (RR=1.17, 95% CI 1.04–1.32, P=0.01) and spinal cord compression-free survival (RR=1.21, 95% CI 1.07–1.36, P=0.003), log-transformed serum alkaline phosphatase activity and age were not
significantly associated with survival or spinal cord compression-free survival.
Predictive value of tumour grading
Mean Gleason score was 7.5, with the majority of patients having a Gleason score greater than 7. Patients with a Gleason score equal to or greater than 7 had a significantly shorter survival and spinal cord compression-free survival than their counterparts with a score of less than 7. Median survival for Gleason ≥7 vs Gleason <7 was 6.8 vs 12.7 months (P<0.03) and median spinal cord
RR=2.33 (P=0.013) for mortality and RR=2.37 (P=0.003) for spinal cord compression.
Predictive value of bone scintigraphy
The predictive value of the conventional Soloway method of grading skeletal metastases for survival and spinal cord compression-free survival is shown in Table 1. The Soloway method of grading metastases was overall significantly predictive for survival (P=0.008) and spinal cord compression-free survival (P=0.031), but this was no longer the case after adjusting for confounders such as PSA concentrations, serum alkaline phosphatase activity and age (after such adjustment, P=0.09 and 0.35 respectively). The new method of analysing bone scintigrams, which concentrates on the extent of vertebral spine involvement, was able to significantly predict spinal cord compression (P<0.0001) and its level, as illustrated in Table 2 and Fig. 1.
Table 1 Predictive value of the Soloway grading method for survival and spinal cord compression (SCC)-free survival in patients with hormone-refractory prostate cancer
Grade No. of patients RR, survivala P value RR, SCC-free survivala P value
0 0 1 11 1 1 2 23 2.29 (1.03–5.07) 1.96 (0.89–4.29) 3 24 1.85 (0.84–4.07) 1.72 (0.79–3.75) 4 26 3.66 (1.67–8.06) 3.03 (1.40–6.56) 0.008 0.031 a
Table 2 Incidence of spinal cord compression (SCC) in patients with total or partial involvement of a vertebra on bone scintigraphy
All patients SCC No SCC P value Vertebral involvement (n=84) (n=20) (n=64) Total 22 18 4 Partial 62 2 60 <0.0001 Discussion
Skeletal metastases occur in 30–70% of all cancer patients12,13 and autopsy studies demonstrate the presence of skeletal metastases in up to 84% of patients with prostate cancer3,14-17. More than 80% of skeletal metastases involve the axial skeleton rich in red bone marrow, 40% affect the vertebral bodies, and lesions may involve the intradural and intramedullary spaces4,18-28. Skeletal metastases are associated with an increased incidence of fractures, particularly when osteolytic, and with an increased risk of spinal cord compression, particularly when
this complication would therefore be of clinical relevance in that it would enable early institution of treatment.
A diagnosis of prostate cancer is suspected on the basis of an elevated PSA concentration. The malignancy is confirmed by histological evaluation of needle biopsy material and the tumour is subsequently staged to allow therapeutic decision-making. PSA is considered to be the most accurate and specific marker for prostate cancer as it is produced by the prostate and is specific for prostatic tissue28. High serum concentrations of this tumour marker are consequently highly likely to predict skeletal tumour burden and hence risk of spinal cord compression, as also confirmed in the present study. The widespread availability of PSA
measurements has led to the view that bone scintigraphy is no longer necessary or relevant in the management of the patient with prostate cancer. However, not all prostate cancer patients who display large increases in PSA concentrations develop spinal cord compression in the late stages of their malignancy, and this marker is certainly not able to predict the spinal level threatened by this
complication.
Bone scintigraphy using 99mTc-MDP is one of the most sensitive and widely used methods for the diagnosis of bone metastases, detecting one-third to one-half of metastatic lesions not seen on conventional radiology33-37. Plain radiographs require a lesion to be more than 1 cm in size, with 50% loss of trabecular bone, before it is readily visible38. By contrast, the false negative rate for the diagnosis of skeletal metastases on bone scintigraphy has been demonstrated to be only 0.08% in one of the largest studies of breast cancer patients39.
Radionuclide uptake depends partly on local blood flow, but largely on local osteoblastic activity, so that predominantly osteoblastic metastases can be clearly distinguished from surrounding normal skeletal uptake. In prostate cancer, bone scintigraphy is thus extremely sensitive to both progression and regression of the metastatic process, so it is likely to have strong prognostic implications. It seems logical, therefore, to perform bone scintigraphy in patients with prostate cancer with new or worsening skeletal symptoms, at any stage of their disease,
References
1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics 1996. CA Cancer J Clin 1996; 46:5-27
2. McKillop JH. Bone scanning in metastatic disease. In Fogelman I, ed. Bone scanning in clinical practice. Berlin Heidelberg New York: Springer; 1996; 51–60
3. Jacobs SC. Spread of prostatic cancer to bone. Urology 1983; 21:337–344. 4. Gilbert RW, Kim JH, Posner JB. Epidural spinal cord compression from
metastatic tumor; diagnosis and treatment. Ann Neurol 1978; 3:40–51. 5. Soerdjbalie-Maikoe V, Pelger RCM, Lycklama à Nijeholt AAB, Arndt JW,
Zwinderman AH, Papapoulos SE, Hamdy NAT. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord
compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med Mol Imaging 2002; 29:494–498.
6. Osborn JL, Getzenberg RH, Trump DL. Spinal cord compression in prostate cancer. J Neurooncol 1995; 23:135–147.
7. Flynn DF, Shipley WU. Management of spinal cord compression secondary to metastatic prostatic carcinoma. Urol Clin North Am 1991; 18:145–152. 8. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rev
1966; 50:125–128.
9. Gleason D, Mellinger G and the Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic
adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111:58–64.
11. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61:195–202
12. Silverberg E, Lubera J. Cancer statistics. CA Cancer J Clin 1987; 37:2–1 13. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma. Analysis of 1000
autopsy cases. Cancer 1950; 2:74–85.
14. Franks LM. The spread of prostatic carcinoma. J Pathol Bacteriol 1956; 72:603–611.
15. Abrams HL. Skeletal metastases in carcinoma. Radiology 1950; 55:534–538 16. Turner JW, Jaffe HL. Metastatic neoplasms. A clinical and roentgenological study of involvement of skeleton and lungs. Am J Roentgenol 1940; 43:479– 492
17. Elkin M, Mueller HP. Metastases from cancer of the prostate. Cancer 1954; 7:1246–1248.
18. Wong DA, Fornasier VL, MacNab I. Spinal metastases: the obvious, the occult and the impostors. Spine 1990; 15:1–4.
19. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol 1991; 9:509–524.
20. Miller F, Whitehill R. Carcinoma of the breast metastatic to the skeleton. Clin Orthop 1984; 184:121–127.
21. Krishnamurthy GT, Tubis M, Hiss J, et al. Distribution pattern of metastatic bone disease. A need for total body skeletal image. JAMA 1977; 237:2504– 2506.
22. Byrne TN. Spinal cord compression from epidural metastases. N Engl J Med 1992; 327:614–619.
23. Berrettoni BA, Carter JR. Mechanisms of cancer metastasis to bone. J Bone Joint Surg Am 1986; 68:308–312
24. Willems A. Secondary tumours of bones. In: The spread of tumours in the human body, 3rd edn. London: Butterworth; 1973:229–250
26. Biersack HJ, Wegner G, Distelmaier W. Bone metastases of prostate cancer in relation to tumour size and grade of malignancy. Nuklearmedizin 1980; 19:29– 32.
27. Shih WJ, Mitchell B, Wierzbinski B. Prediction of radionuclide bone imaging findings by Gleason histologic grading of prostate carcinoma. Clin Nucl Med 1991; 16:763–766.
28. Chybowski FM, Keller JJL, Bergstrahl EJ. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145:313–318.
29. Barron KD, Hirano A, Araki S, Terry RD. Experiences with metastatic neoplasms involving the spinal cord. Neurology 1959; 9:91.
30. Bruckman JE, Bloomer WD. Management of spinal cord compression. Semin Oncol 1978; 5:135–140.
31. Gilbert RW, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumors: diagnosis and treatment. Ann Neurol 1978; 3:40–51. 32. Ruff RL, Lanska DJ. Epidural metastases in prospectively evaluated veterans
with cancer and back pain. Cancer 1989; 63:2234–2241.
33. McGregor B, Tulloch AG, Quinlan MF, et al. The role of bone scanning in the assessment of prostatic carcinoma. Br J Urol 1978; 50:178–181.
34. O Donoghue EP, Constable AR, Sherwood T, et al. Bone scanning and plasma phosphatases in carcinoma of the prostate. Br J Urol 1978; 50:172– 177.
35. Buck AC, Chisholm GD, Merrick MV, et al. Serial fluorine-18 bone scans in the follow up of carcinoma of the prostate. Br J Urol 1975; 47:287–294. 36. Merrick MV, Stone AR, Chisholm GD. Prostatic cancer. Nuclear medicine.
Recent Results Cancer Res 1981; 78:108–118.
37. Pollen JJ, Gerber K, Ashburn WL, et al. The value of nuclear bone imaging in advanced prostatic cancer. J Urol 1981; 125:222–223.
38. Edelstyn GA, Gillespie PJ, Grebbel FS. The radiological demonstration of osseous metastases: experimental observations. Clin Radiol 1967; 18:158–162. 39. Coleman RE, Rubens RD, Fogelman I. Reappraisal of the baseline bone scan
